Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORN252 in Healthy Participants
NCT07439796Phase 1Recruiting
- Sponsor
- Orna Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ORN252 in B-cell malignancy, sponsored by Orna Therapeutics. Primary endpoint: Incidence and severity of safety, clinical, and laboratory abnormalities at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
ORN252
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07439796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439796.